Sugammadex + Succinylcholine + Rocuronium
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anesthesia, General
Conditions
Anesthesia, General
Trial Timeline
Feb 10, 2006 → Sep 9, 2006
NCT ID
NCT00474253About Sugammadex + Succinylcholine + Rocuronium
Sugammadex + Succinylcholine + Rocuronium is a phase 3 stage product being developed by Merck for Anesthesia, General. The current trial status is completed. This product is registered under clinical trial identifier NCT00474253. Target conditions include Anesthesia, General.
What happened to similar drugs?
1 of 20 similar drugs in Anesthesia, General were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00474253 | Phase 3 | Completed |
Competing Products
20 competing products in Anesthesia, General